SOBI (SOBI) Investor presentation summary

Strategic direction and business model

• Focus on rare disease therapies with a proven track record in partnerships and acquisitions to build a robust pipeline.

• Deep clinical-stage pipeline spans multiple rare disease areas, with 13 primary medicines on the market.

• Ambition to double revenue to SEK 55bn by 2030, driven by six major launches and five potential blockbusters.

• Global expansion with >100 launches in five years and new organizations in Japan, Australia, Korea, and Brazil.

• Strategy evolving to address broader populations while maintaining a rare disease core.

Financial performance and outlook

• Achieved SEK 15,025M revenue in H1 2026, representing 26% growth at constant exchange rates.

• Delivered a 12% revenue CAGR from 2020-2025 and expanded adjusted EBITA margin to 40% in 2025.

• Q2 2026 saw 29% growth at CER and a 35% adjusted EBITA margin, with strong performance across all regions.

• Upgraded 2026 outlook: revenue expected to grow mid- to high-teens percent at CER, with adjusted EBITA margin in the mid- to high-30s.

• Strong cash generation supports reinvestment, disciplined business development, and shareholder value creation.

Product and pipeline highlights

• Six major launches planned, including Altuvoct, Gamifant, Aspaveli, NASP, Tryngolza, and pozdeutinurad.

• Altuvoct sales up 149% YoY in Q2 2026, launched in 30 countries, with further expansion planned.

• Aspaveli launch progressing, with expanding evidence base and new device rollout; on track for 400-500 nephrology patients by 2026.

• Doptelet and Gamifant continue strong global growth, with Doptelet expanding in Asia and Gamifant filings in EU and Japan.

• Pipeline catalysts include regulatory decisions, pivotal trial readouts, and new launches through 2027.